SCHEMBL1840334

SCHEMBL1840334

Cc1ccc(Oc2ccccc2P(c2ccccc2)c2ccccc2Oc2ccc(C)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.45
SLC6A4 P31645 2/20 0.45
HTT P42858 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 3/20 0.44
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FFAR1 O14842 1/20 0.39
RIPK1 Q13546 1/20 0.38
TOP1 P11387 1/20 0.38
TEAD4 Q15561 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
POLB P06746 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
CYP3A4 P08684 1/20 0.37
CASP1 P29466 1/20 0.36
MAPT P10636 2/20 0.36
TRIM24 O15164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1834532 0.89 HTR2A (0.50) HTR2ASLC6A4HTTSMN1; SMN2LMNA
SCHEMBL1838565 0.87 TSHR (0.44) SLC6A4HTTLMNAALDH1A1MAPK1
SCHEMBL10976813 0.83 TSHR (0.44) SLC6A4HTTLMNAALDH1A1MAPK1
SCHEMBL1836758 0.79 ALDH1A1 (0.39) SLC6A4HTTLMNAALDH1A1MAPK1
SCHEMBL101880 0.77 CYP3A4 (0.50) HTTTOP1TDP1CYP3A4
SCHEMBL11585106 0.77 ALDH1A1 (0.60) HTR2ASLC6A4HTTSMN1; SMN2LMNA
SCHEMBL1840257 0.77 LTA4H (0.50) SLC6A4HTTLMNAALDH1A1MAPK1
SCHEMBL2608310 0.77 HTT (0.65) HTR2ASLC6A4HTTSMN1; SMN2LMNA
SCHEMBL17529737 0.77 CA1 (0.44) HTTSMN1; SMN2LMNAALDH1A1MAPK1
SCHEMBL17674561 0.75 CYP3A4 (0.48) TOP1TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 HTR2A 383/4885SLC6A4 4019/4885HTT 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.